RVIV · Reviv3 Procare Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $26.26M | $27.50M | $23.52M | $2.34M | $1.63M | $1.01M |
| Cost of Revenue | $7.62M | $7.30M | $5.81M | $828.6K | $599.7K | $480.8K |
| Gross Profit | $18.64M | $20.19M | $17.71M | $1.51M | $1.03M | $531.9K |
| R&D | - | - | - | - | - | - |
| SG&A | $1.70M | $1.69M | $1.28M | $271.9K | $281.9K | $270.3K |
| Total Operating Expenses | $17.48M | $18.69M | $15.73M | $1.72M | $1.35M | $703.1K |
| D&A | $148.5K | $130.6K | $7.9K | $7.9K | $10.0K | $10.5K |
| Operating Income | $1.16M | $1.50M | $1.98M | ($211.4K) | ($321.1K) | ($171.1K) |
| Interest Expense | $0 | $4.4K | $2.5K | $6.5K | $6.1K | $1.8K |
| Income Tax | $453.8K | ($220.2K) | $230.9K | - | - | - |
| Net Income | $855.0K | $2.00M | $1.82M | ($182.9K) | ($297.8K) | ($172.8K) |
| EPS - Basic | $0.13 | $0.57 | $0.00 | - | - | - |
| EPS - Diluted | $0.10 | $0.21 | $0.00 | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.77M | $3.25M | $4.83M | $373.7K | $496.9K | $409.0K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $2.53M | $3.39M | $1.31M | $323.4K | $490.9K | $288.1K |
| Accounts Payable | $866.6K | $967.6K | $908.6K | $435.7K | $436.1K | $98.6K |
| Current Assets | $9.26M | $7.97M | $7.36M | $803.0K | $1.04M | $893.1K |
| Total Assets | $12.87M | $10.97M | $10.17M | $893.9K | $1.26M | $1.14M |
| Current Liabilities | $2.46M | $2.80M | $2.85M | $707.0K | $712.4K | $339.8K |
| Long-term Debt | $140.2K | $146.6K | $172.6K | - | - | - |
| Total Liabilities | $3.21M | $3.28M | $3.50M | $709.2K | $917.1K | $638.3K |
| Stockholders' Equity | $9.66M | $7.70M | $6.67M | $184.7K | $345.6K | $504.6K |
| Retained Earnings | $720.7K | ($134.3K) | ($3.47M) | ($5.29M) | ($5.11M) | ($4.81M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.93M | $2.7K | $2.92M | ($126.1K) | $48.4K | ($89.7K) |
| Investing Cash Flow | ($394.3K) | ($160.5K) | $1.00M | - | ($15.4K) | ($9.2K) |
| Financing Cash Flow | ($18.4K) | ($1.42M) | $540.1K | $2.8K | $54.9K | $161.8K |
| CapEx | $213.5K | $138.4K | $65.7K | - | $15.4K | $9.2K |
| Free Cash Flow | $1.72M | ($135.8K) | $2.85M | - | $33.0K | ($98.9K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71.0% | 73.4% | 75.3% | 64.5% | 63.3% | 52.5% |
| Operating margin | 4.4% | 5.5% | 8.4% | -9.0% | -19.7% | -16.9% |
| EBITDA margin | 5.0% | 5.9% | 8.5% | -8.7% | -19.0% | -15.9% |
| Net margin | 3.3% | 7.3% | 7.8% | -7.8% | -18.2% | -17.1% |
| Free cash flow margin | 6.5% | -0.5% | 12.1% | - | 2.0% | -9.8% |
| FCF / Net income | 2.01 | -0.07 | 1.56 | - | -0.11 | 0.57 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 6.5% | 6.1% | 5.5% | 11.6% | 17.3% | 26.7% |
| Effective tax rate | 34.7% | -12.4% | 11.2% | - | - | - |
| Return on assets | 6.6% | 18.3% | 17.9% | -20.5% | -23.6% | -15.1% |
| Return on equity | 8.9% | 26.0% | 27.3% | -99.0% | -86.1% | -34.2% |
| Return on invested capital | 7.7% | 19.2% | 25.7% | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.76 | 2.85 | 2.58 | 1.14 | 1.46 | 2.63 |
| Quick ratio | 2.73 | 1.63 | 2.12 | 0.68 | 0.77 | 1.78 |
| Cash ratio | 1.94 | 1.16 | 1.69 | 0.53 | 0.70 | 1.20 |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.02 | 0.03 | - | - | - |
| Debt / Assets | 0.01 | 0.01 | 0.02 | - | - | - |
| Debt / EBITDA | 0.11 | 0.09 | 0.09 | - | - | - |
| Interest coverage | - | 342.3x | 787.1x | -32.3x | -52.8x | -97.7x |
| Equity multiplier | 1.33 | 1.43 | 1.52 | 4.84 | 3.65 | 2.26 |
| Liabilities / Assets | 0.25 | 0.30 | 0.34 | 0.79 | 0.73 | 0.56 |
| Efficiency | ||||||
| Asset turnover | 2.04 | 2.51 | 2.31 | 2.61 | 1.29 | 0.89 |
| Inventory turnover | 3.01 | 2.15 | 4.43 | 2.56 | 1.22 | 1.67 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 121d | 170d | 82d | 142d | 299d | 219d |
| Days payable outstanding | 42d | 48d | 57d | 192d | 265d | 75d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -4.5% | 16.9% | 906.8% | 43.0% | 61.3% | 8.5% |
| Revenue CAGR (3y) | 124.0% | 156.3% | 185.3% | 35.8% | 41.1% | - |
| Revenue CAGR (5y) | 91.8% | 96.7% | 109.6% | - | - | - |
| Gross profit growth (YoY) | -7.7% | 14.0% | 1074.7% | 45.8% | 94.4% | 21.0% |
| Operating income growth (YoY) | -22.7% | -24.2% | - | 34.2% | -87.6% | -14.4% |
| Net income growth (YoY) | -57.3% | 9.8% | - | 38.6% | -72.3% | -15.2% |
| EPS growth (YoY) | -52.4% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | 47.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 25.5% | 15.3% | 3512.1% | -46.6% | -31.5% | -25.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Business segments
$52.52M totalConsolidated$26.26M · 50.0%
Hearing Enhancement And Protection$24.74M · 47.1%
Hair Care And Skin Care$1.52M · 2.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
4.01
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations
Comparing Reviv3 Procare Co against the 5 most active filers in the same SIC group.